Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OLMABullishCorporate Developmentsnews

High materiality8/10

Olema Advances Palazestrant; OPERA-01 Readout Expected 1Q2027; Bayer Collaboration

Aug 10, 2026, 4:04 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Key catalysts (1Q2027 OPERA-01 readout, Bayer collaboration) could re-rate probability of success and potential peak sales; a robust cash position supports execution and reduces near-term dilution risk.

AI summary

What happened, with direct paths to the underlying reporting

Olema reported Q2 2026 results with a completed OPERA-01 enrollment and guidance for first-quarter 2027 top-line palazestrant data. The company also highlighted encouraging OP-3136 Phase 1 signals and a Bayer collaboration to test OP-3136 with darolutamide in mCRPC. Cash runway remains robust at $461.1M, supporting late-stage trials and potential commercial preparation.

Completed enrollment in OPERA-01 Phase 3; top-line data expected Q1 2027.
OP-3136 Phase 1 data shown at ASCO 2026; Bayer collaboration announced.
Bayer collaboration to evaluate OP-3136 with darolutamide in mCRPC.
Q2 2026 cash and investments: $461.1M; net loss $63.2M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.